Cormorant Asset Management, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001583977
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 50 positions · Total reported value $1.95B · Top-10 concentration 59.2% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 82.8% · 12 new · 28 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +14.2% · vs SPY -0.7% · Prev Value $1.93B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, Cormorant Asset Management, LP disclosed 50 equity positions with a combined reported value of $1.95B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.2% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were PRAX ($214.27M), BBOT ($136.23M), PBLS ($126.33M). By sector, the heaviest allocations are Health Care 93.3%, Industrials 5.1%. Versus the prior quarter, allocation shifted toward Health Care (+3.5pp) and away from Other (-3.3pp).
Versus the prior quarter, Cormorant Asset Management, LP opened 12 new positions, trimmed 28 and fully exited 8, a turnover rate of 82.8% of positions. The portfolio's overlap with the prior quarter was 66% of names.
The largest new positions opened in Q2 2026 were PBLS ($126.33M), CLYM ($27.46M), SYRE ($19.98M).
Of the 8 positions fully exited versus the prior quarter, the largest were CNTA ($41.71M), MAZE ($22.39M), TERN ($15.82M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Fully Exited (vs previous quarter)
- CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $41.71M
- MAZE MAZE THERAPEUTICS INC · prev qtr: $22.39M
- TERN TERNS PHARMACEUTICALS INC · prev qtr: $15.82M
- ZURA ZURA BIO LTD · prev qtr: $8.63M
- AXSM AXSOME THERAPEUTICS INC. · prev qtr: $8.45M
- GLUE MONTE ROSA THERAPEUTICS INC · prev qtr: $6.58M
- RLYB RALLYBIO CORP · prev qtr: $3.59M
- CNTX CONTEXT THERAPEUTICS INC · prev qtr: $1.39M
Insider Transactions (Form 4)
Latest Cormorant Asset Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-29 | Sell | Corbus Pharmaceuticals Holdings, Inc. | 425,000 | $4.10 | SEC filing |
| 2026-08-10 | Buy | BlossomHill Therapeutics, Inc. | 312,500 | $16.00 | SEC filing |
| 2026-08-10 | Conversion | BlossomHill Therapeutics, Inc. | 1,701,541 | — | SEC filing |
| 2026-08-10 | Conversion | BlossomHill Therapeutics, Inc. | 1,599,993 | — | SEC filing |
| 2026-04-28 | Sell | BRIGHT MINDS BIOSCIENCES INC. | 109,331 | $89.50 | SEC filing |
Fund Profile
Cormorant Asset Management, LP, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 50 positions worth $1.95B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-79513 (status: Approved), registered 2014-04-15
- Regulatory AUM (Form ADV): $3.84B as of 2026-05-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 7 private funds, of which 1 hedge funds
Portfolio Structure
- 50 positions · $1.95B reported value (Q2 2026)
- Top 10 holdings = 59.2% of reported value
- Largest position: PRAX (PRAXIS PRECISION MEDICINES I) at 11.0%
- Average position size: $39.03M
Sector Tilt
- Health Care 93.3%
- Industrials 5.1%
- Financials 0.9%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 12 new, 5 added, 28 reduced, 8 exited
- 5 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
640.00K | $214.27M | 10.98% | Reduce | |
| 2 |
|
17.88M | $136.23M | 6.98% | Hold | |
| 3 |
|
4.62M | $126.33M | 6.47% | New | |
| 4 |
|
2.66M | $110.74M | 5.67% | Reduce | |
| 5 |
|
6.00M | $109.92M | 5.63% | Add | |
| 6 |
|
2.51M | $101.98M | 5.23% | Reduce | |
| 7 |
|
7.00M | $100.10M | 5.13% | Reduce | |
| 8 |
|
3.29M | $92.46M | 4.74% | Reduce | |
| 9 |
|
675.00K | $89.95M | 4.61% | Reduce | |
| 10 |
|
750.00K | $73.11M | 3.75% | Reduce | |
| 11 |
|
900.00K | $63.18M | 3.24% | Reduce | |
| 12 |
|
3.21M | $62.41M | 3.20% | Reduce | |
| 13 |
|
2.39M | $58.59M | 3.00% | Reduce | |
| 14 |
|
533.34K | $50.76M | 2.60% | Hold | |
| 15 |
|
3.98M | $45.75M | 2.34% | Add | |
| 16 |
|
550.00K | $40.96M | 2.10% | Reduce | |
| 17 |
|
1.30M | $40.64M | 2.08% | Reduce | |
| 18 |
|
2.61M | $38.84M | 1.99% | Add | |
| 19 |
|
2.47M | $32.00M | 1.64% | Hold | |
| 20 |
|
550.00K | $30.36M | 1.56% | Reduce | |
| 21 |
|
2.11M | $27.46M | 1.41% | New | |
| 22 |
|
2.15M | $26.90M | 1.38% | Add | |
| 23 |
|
1.00M | $26.01M | 1.33% | Reduce | |
| 24 |
|
750.00K | $25.93M | 1.33% | Reduce | |
| 25 |
|
2.34M | $22.00M | 1.13% Form 4 · 1 → |
Hold | |
| 26 |
|
225.00K | $19.98M | 1.02% | New | |
| 27 |
|
400.00K | $18.82M | 0.96% | New | |
| 28 |
|
500.00K | $16.95M | 0.87% | Reduce | |
| 29 |
|
475.00K | $16.81M | 0.86% | Reduce | |
| 30 |
|
5.00M | $15.55M | 0.80% | Reduce | |
| 31 |
|
1.30M | $13.81M | 0.71% | Hold | |
| 32 |
|
50.00K | $13.34M | 0.68% | Reduce | |
| 33 |
|
550.00K | $12.12M | 0.62% | New | |
| 34 |
|
75.00K | $8.00M | 0.41% | Reduce | |
| 35 |
|
1.03M | $7.66M | 0.39% | Add | |
| 36 |
|
150.00K | $7.61M | 0.39% | New | |
| 37 |
|
100.00K | $6.29M | 0.32% | Reduce | |
| 38 |
|
3.57M | $6.25M | 0.32% | New | |
| 39 |
|
125.00K | $4.68M | 0.24% | Reduce | |
| 40 |
|
175.00K | $4.59M | 0.23% | Reduce | |
| 41 |
|
50.00K | $4.08M | 0.21% | Reduce | |
| 42 |
|
75.00K | $4.03M | 0.21% | Reduce | |
| 43 |
|
370.00K | $3.96M | 0.20% | New | |
| 44 |
|
100.00K | $3.87M | 0.20% | Reduce | |
| 45 |
|
1.25M | $3.80M | 0.20% | New | |
| 46 |
|
200.00K | $3.59M | 0.18% | Reduce | |
| 47 |
|
175.00K | $3.27M | 0.17% | New | |
| 48 |
|
50.00K | $2.91M | 0.15% | Reduce | |
| 49 |
|
1.00M | $2.50M | 0.13% | New | |
| 50 |
|
5.50K | $100.01K | 0.01% | New | |
Loading forecast…
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q2)
P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)
Historical Backtest (10 quarters)
Avg precision 65% · recall 65% · F1 65% · avg rank error 3.1 · Top-10 turnover 34%
| Quarter | Prec. | Recall | F1 | Predicted Top 10 | Actual Top 10 |
|---|---|---|---|---|---|
| 2024-Q1 | 50% | 50% | 50% | MLTX · AMAM · EYPT · BBIO · ACLX · RYZB · ALXO · ALPN · BMEA · PHVS | MLTX · EYPT · ACLX · ALPN · BBIO · PRAX · CRBP · TARS · LBPH · EWTX |
| 2024-Q2 | 60% | 60% | 60% | MLTX · EYPT · ACLX · ALPN · BBIO · PRAX · CRBP · TARS · LBPH · EWTX | MLTX · CRBP · ACLX · PCVX · LBPH · EYPT · RAPP · CRNX · EWTX · MRUS |
| 2024-Q3 | 90% | 90% | 90% | MLTX · CRBP · PCVX · ACLX · LBPH · EYPT · RAPP · CRNX · EWTX · MRUS | MLTX · PCVX · ACLX · LBPH · EWTX · EYPT · RAPP · CRNX · PRAX · CRBP |
| 2024-Q4 | 60% | 60% | 60% | MLTX · PCVX · ACLX · EWTX · LBPH · EYPT · RAPP · CRNX · RNAM · CRBP | MLTX · PRAX · JANX · ACLX · EWTX · NAMS · EYPT · RAPP · CRNX · INSM |
| 2025-Q1 | 60% | 60% | 60% | MLTX · PRAX · JANX · ACLX · EWTX · NAMS · EYPT · RAPP · CRNX · CNTA | MLTX · EWTX · BBIO · ACLX · PRAX · EYPT · INSM · DRUG · HLXB · CNTA |
| 2025-Q2 | 70% | 70% | 70% | MLTX · EWTX · PRAX · BBIO · ACLX · EYPT · INSM · DRUG · HLXB · CNTA | MLTX · EYPT · BBIO · PRAX · MRUS · EWTX · INSM · ACLX · NAMS · JANX |
| 2025-Q3 | 60% | 60% | 60% | MLTX · EYPT · BBIO · PRAX · MRUS · EWTX · INSM · ACLX · NAMS · JANX | BBOT · ABVX · EYPT · RAPP · BBIO · EWTX · DRUG · ACLX · INSM · NAMS |
| 2025-Q4 | 60% | 60% | 60% | BBOT · ABVX · EYPT · RAPP · BBIO · NAMS · EWTX · DRUG · INSM · ACLX | PRAX · BBOT · ABVX · QQQ · EYPT · IWM · XBI · RAPP · BBIO · DRUG |
| 2026-Q1 | 50% | 50% | 50% | PRAX · BBOT · ABVX · QQQ · EYPT · IWM · XBI · RAPP · BBIO · DRUG | PRAX · BBOT · EYPT · EWTX · ERAS · RAPP · ALMS · ABVX · MLTX · DNTH |
| 2026-Q2 ★ | 90% | 90% | 90% | PRAX · BBOT · EYPT · EWTX · MLTX · ALMS · ERAS · RAPP · DNTH · ABVX | PRAX · BBOT · PBLS · RAPP · ERAS · EWTX · EYPT · ALMS · ABVX · DNTH |
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
FAQ
What did Cormorant Asset Management, LP buy in 2026-Q2?
In its 2026-Q2 13F filing, Cormorant Asset Management, LP reported 50 equity positions worth $1.95B in aggregate; its largest disclosed positions were PRAX ($214.27M), BBOT ($136.23M), PBLS ($126.33M).
How large is Cormorant Asset Management, LP's portfolio?
Cormorant Asset Management, LP reported $1.95B of long equity holdings across 50 positions as of 2026-Q2. Top-10 holdings account for 59.2% of reported value.
What is Cormorant Asset Management, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.